Neurodegenerative disease management最新文献

{"title":"Comparing balance using the BESTest in Alzheimer, Huntington and Parkinson disease.","authors":"Lauren E Tueth, Ryan P Duncan, Beth E Crowner, Gammon M Earhart","doi":"10.1080/17582024.2024.2388507","DOIUrl":"10.1080/17582024.2024.2388507","url":null,"abstract":"<p><p><b>Aim:</b> Individuals with Alzheimer disease (AD), Huntington disease (HD) and Parkinson disease (PD) have impaired balance, and comparing these deficits could improve management of neurological diseases.<b>Methods:</b> Scores on the Balance Evaluation Systems Test (BESTest) were compared across three groups, consisting of individuals with AD, HD and PD in early stages of their respective disease.<b>Results:</b> Individuals with PD had significantly higher scores on the BESTest than individuals with AD (95% CI [4.30, 21.37], <i>p</i> < 0.01) or HD (95% CI [6.53, 24.18], <i>p</i> < 0.001). Individuals with AD and HD were not significantly different on the overall BESTest or any of its subsections.<b>Conclusion:</b> AD and HD may have overlapping pathologies resulting in early and similar balance impairments in these groups.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"87-96"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary.","authors":"Paul Kamudoni, Dagmar Amtmann, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Pavle Repovic, Kevin N Alschuler, Gloria von Geldern, Annette Wundes, Amy Barrett, Oyebimpe Olayinka-Amao, Christian Henke","doi":"10.1080/17582024.2024.2357002","DOIUrl":"10.1080/17582024.2024.2357002","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary describes how researchers worked with people with multiple sclerosis (MS), neurologists and measurement experts to create an easy-to-use questionnaire to measure the physical function of people with MS. This questionnaire covers topics that are relevant and important to people with MS and their doctors.The ability to do what you want to do, when you want to do it, is one of the most important concerns for people with MS. This questionnaire could help doctors to record and manage how much MS affects people's lives.MS can bring a range of challenging symptoms such as '<b>brain fog</b>', tiredness, and problems with movement and balance. Many of these symptoms can make day-to-day activities, like working, very difficult for people with MS. Doctors currently use examinations like the <b>Expanded Disability Status Scale (EDSS)</b> and the <b>MS Functional Composite (MSFC)</b>, but these do not fully consider what is important to people living with MS. A questionnaire that specifically measures <b>physical functioning</b> of people with MS could help doctors and people with MS to better understand, communicate and manage the physical effects of MS. In this study, people with MS were asked to help create a questionnaire about physical function that reflects topics that are important to them.</p><p><strong>What were the results?: </strong>The PROMIS^®nq physical function - Multiple Sclerosis 15a (the PROMIS^® PF MS questionnaire) was successfully created with the help of people with MS. People with MS thought that the PROMIS^® PF MS questionnaire covered issues important to their physical function. Scores were in line with results of other physical symptom measurement scales like the EDSS.</p><p><strong>What do the results mean?: </strong>The PROMIS^® PF MS questionnaire could be used to meaningfully record physical function among people with MS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"119-125"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological activities of astaxanthin in the treatment of neurodegenerative diseases.","authors":"Alireza Lotfi, Zahra Abroodi, Mozafar Khazaei","doi":"10.1080/17582024.2024.2433932","DOIUrl":"10.1080/17582024.2024.2433932","url":null,"abstract":"<p><strong>Introduction: </strong>Neurodegenerative diseases (NDs) develop with the gradual advancement of neuronal damage and dysfunction in the central nervous system (CNS). These disorders are mostly the outcomes of the improper sedimentation and accumulation of proteins, such as amyloid-β (Aβ), α-synuclein, and prions. Astaxanthin (AST) exists in different types of living organisms and displays antioxidant and anti-inflammatory functions. This review has concentrated on the therapeutic characteristics of AST on NDs.</p><p><strong>Methods: </strong>Data was collected by searching Scopus, PubMed, and Google Scholar databases. Articles selected for this review reported results on the neuroprotective properties of AST on NDs of studies conducted during the years 2000 to 2024.</p><p><strong>Results: </strong>AST decreases soluble Aβ levels by stimulating the Aβ degradation enzyme. It also reduces inflammation in the substantia nigra (SN) by decreasing IBA1 expression, thereby lessening microglia activity. This carotenoid reduces demyelination by increasing the survival of oligodendrocytes cells and increasing the number of their progenitor cells. AST has antioxidant, anti-inflammatory, and anti-apoptotic properties and can play a role in the treatment of many NDs.</p><p><strong>Conclusion: </strong>There is no definitive treatment for some NDs. The use of AST and natural compounds can be an optimal method for preventing and treating NDs with few side effects.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"241-256"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A discussion with Philippe Huot: the challenges of discovering novel therapies for the treatment of Parkinson's disease.","authors":"Philippe Huot","doi":"10.1080/17582024.2024.2389034","DOIUrl":"10.1080/17582024.2024.2389034","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"127-129"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on nonviral, nonbacterial infectious agents toxicity involved in neurodegenerative diseases.","authors":"Mohammad Taheri, Ali Bahrami, Kiana Kimiaei Asadi, Mojdeh Mohammadi, Pejman Molaei, Mehrdad Hashemi, Fatemeh Nouri","doi":"10.2217/nmt-2023-0004","DOIUrl":"10.2217/nmt-2023-0004","url":null,"abstract":"<p><p>Neuronal death, decreased activity or dysfunction of neurotransmitters are some of the pathophysiological reasons for neurodegenerative diseases like Alzheimer's, Parkinson's and multiple sclerosis. Also, there is evidence for the role of infections and infectious agents in neurodegenerative diseases and the effect of some metabolites in microorganisms in the pathophysiology of these diseases. In this study, we intend to evaluate the existing studies on the role of infectious agents and their metabolites on the pathophysiology of neurodegenerative diseases. PubMed, Scopus, Google Scholar and Web of Science search engines were searched. Some infectious agents have been observed in neurodegenerative diseases. Also, isolations of some fungi and microalgae have an improving effect on Parkinson's and Alzheimer's.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"351-369"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139735730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study of once-a-week donepezil transdermal system's bioequivalence to oral donepezil in healthy volunteers: a plain language summary.","authors":"Rene Braeckman, Charles Oh","doi":"10.2217/nmt-2023-0012","DOIUrl":"10.2217/nmt-2023-0012","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;What is this summary about?: &lt;/strong&gt;This is a plain language summary of an article published in the &lt;i&gt;Journal of Alzheimer's Disease&lt;/i&gt;. It describes an adhesive patch placed on the skin's surface, also referred to as a transdermal delivery system (or TDS), that delivers donepezil (called donepezil TDS going forward) through the skin of patients with mild, moderate, and severe dementia of the Alzheimer's type. This summary focuses on how fast and how much of the medication donepezil enters the body through the skin, and how it compares with taking a pill form of donepezil by mouth (oral donepezil). This summary also looks at how much donepezil is circulating through the body with the use of the once-a-week donepezil TDS versus the once-a-day donepezil pill. We show that the same amount of donepezil circulates through the body when donepezil TDS is used once a week as when a participant takes an oral donepezil pill once a day.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Why is this study important?: &lt;/strong&gt;Dementia is a term used to describe a person's decreasing ability to remember, think, or make decisions necessary to successfully complete daily activities. Alzheimer's disease is a disorder that progresses slowly, with the symptoms of dementia getting worse over many years. When viewed under a microscope, the visible features of Alzheimer's disease within the brain are protein deposits called plaques between brain cells and protein strands within brain cells that appear as tangles. One of the many features that cannot be seen with the naked eye in the Alzheimer's brain is the low level of a chemical called acetylcholine that allows certain nerve cells in the brain involved with memory to communicate with one another. Donepezil, a drug that is widely used to treat dementia associated with Alzheimer's disease, increases the amount of acetylcholine in the brain. Donepezil is usually in pill form and taken by mouth. However, one problem with taking oral donepezil is that it can cause stomach or intestinal side effects like diarrhea, nausea, and vomiting. These side effects may be bad enough that people stop taking their medication. In 2022, for the first time, the United States Food and Drug Administration approved a donepezil TDS marketed under the name Adlarity. Donepezil TDS is for use in patients who have mild, moderate, and severe dementia caused by Alzheimer's disease. It is applied once a week to skin on the patient's back, upper buttocks, or thigh. Donepezil TDS allows the drug donepezil to be absorbed into the body directly through the skin, which means that the drug does not go through the digestive system. This means that many stomach and intestinal side effects (the undesirable effects of the drug) can potentially be reduced.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;What were the results?: &lt;/strong&gt;In healthy volunteers, we showed that donepezil TDS allows a similar amount of the drug into the body as the oral donepezil pill. This is done using a type of examination known as ","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"303-313"},"PeriodicalIF":2.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10218394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An innovative approach to recruiting participants for dementia research: primary care and researcher perspectives.","authors":"Linda Lee, Loretta M Hillier, Tejal Patel, Stephanie K Lu, Michael Lee, Catherine Lee","doi":"10.2217/nmt-2022-0040","DOIUrl":"10.2217/nmt-2022-0040","url":null,"abstract":"<p><p><b>Aim:</b> To describe clinician and researcher perceptions of a new, patient preference focused approach to recruiting patients for research from primary care-based memory clinics. <b>Methods:</b> Memory clinic clinicians completed a survey and key informants completed an individual interview to gather their perceptions of this new program. <b>Results:</b> The majority of clinicians were 'satisfied' or 'very satisfied' with this recruitment approach and indicated that this approach would have minimal negative impact on patient care or create conflict of interest. Key informants valued the program for its patient-centred approach, the integration of research into care and potential for increased recruitment. <b>Discussion:</b> These findings are suggestive of support for this recruitment approach. Pilot testing will inform feasibility, effectiveness and process improvements.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"323-334"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139570774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of the worldwide distribution of <i>LRRK2</i> mutations in Parkinson's disease.","authors":"Hicham El Otmani, Mohamed Daghi, Nadia Tahiri Jouti, Suzanne Lesage","doi":"10.2217/nmt-2023-0025","DOIUrl":"10.2217/nmt-2023-0025","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a neurodegenerative disorder with significant genetic influence. The <i>LRRK2</i> gene is a major genetic contributor, particularly the Gly2019Ser mutation. This focused review investigates the global distribution of <i>LRRK2</i> mutations, with emphasis on Gly2019Ser and other pathogenic variants. Prevalence rates of Gly2019Ser are highest in North Africa and the Ashkenazi-Jewish population, indicating a potential common ancestor and founder effect. Other <i>LRRK2</i> mutations, including Asn1437His, Arg1441Gly/Cys/His, Tyr1699Cys and Ile2020Thr, exhibit varying global prevalences. Understanding these distributions enhances our knowledge of PD genetics and aids personalized medicine. Further research is crucial to unravel clinical implications and develop targeted therapies for <i>LRRK2</i> mutation carriers.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"335-350"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Free-Cog revisited: the diagnostic contribution of cognitive and executive function.","authors":"Andrew J Larner, Alistair Burns","doi":"10.2217/nmt-2023-0013","DOIUrl":"10.2217/nmt-2023-0013","url":null,"abstract":"<p><p><b>Aim:</b> To examine Free-Cog, a recently described, hybrid screening instrument, as separate tests of cognitive (Free-Cog-Cog) and executive function (Free-Cog-Exec) to see if this improved screening accuracy for cognitive impairment compared with standard Free-Cog. <b>Materials & methods:</b> Free-Cog-Cog and Free-Cog-Exec were combined using Boolean logical 'AND' and 'OR' operators (serial and parallel combination), and also used to construct a stepwise decision tree. <b>Results:</b> Serial combination improved specificity and positive predictive value whereas parallel combination improved sensitivity, typical findings with these operators. Stepwise application identified groups with high and low probability of cognitive impairment but failed to differentiate adequately those in the intermediate uncertain diagnosis group. <b>Conclusion:</b> Study findings suggest limited benefit from reformulations of Free-Cog compared with the standard instrument.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"315-321"},"PeriodicalIF":2.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139542855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"People with neuromuscular diseases and their relatives' perspectives on challenges in everyday life and healthcare.","authors":"Charlotte Handberg, Ulla Werlauff","doi":"10.2217/nmt-2023-0008","DOIUrl":"https://doi.org/10.2217/nmt-2023-0008","url":null,"abstract":"<p><p><b>Objective:</b> People with a neuromuscular disease (NMD) often experience challenges in everyday life and healthcare. <b>Aim:</b> To investigate experiences of and perspectives on challenges in everyday life and healthcare of people with NMDs and their relatives to gain new insights into how life-long rehabilitation can be tailored. <b>Patients & methods:</b> The design was qualitative using the interpretive description methodology and the Sense of Coherence theory. An ethnographic fieldwork was conducted where 45 persons with NMD and their relatives were included for interviews and participant observations. <b>Results & conclusion:</b> People with NMDs continually adapt to a changing functioning and balance their need for knowledge with their dependency on help when navigating the healthcare system. Structured, professionally facilitated peer support is needed.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 5","pages":"289-302"},"PeriodicalIF":2.6,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138808120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}